Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
2.890
-0.620 (-17.66%)
At close: Jul 25, 2025, 4:00 PM
2.930
+0.040 (1.38%)
After-hours: Jul 25, 2025, 7:55 PM EDT

Company Description

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.

The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics.

Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.

Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities.

The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation
Absci logo
CountryUnited States
Founded2011
IPO DateJul 22, 2021
IndustryBiotechnology
SectorHealthcare
Employees157
CEOSean McClain

Contact Details

Address:
18105 SE Mill Plain Boulevard
Vancouver, Washington 98683
United States
Phone360 949 1041
Websiteabsci.com

Stock Details

Ticker SymbolABSI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001672688
CUSIP Number00091E109
ISIN NumberUS00091E1091
Employer ID85-3383487
SIC Code8731

Key Executives

NamePosition
Sean McClainFounder, Chief Executive Officer, President and Director
Dr. Zachariah Jonasson Ph.D.Chief Business Officer and Chief Financial Officer
Dr. Andreas Busch Ph.D.Chief Innovation Officer and Member of Scientific Advisory Board
Todd Bedrick CPASenior Vice President and Chief Accounting Officer
Alexander Khan CPAVice President of Finance and Head of Investor Relations
Shelby Walker J.D.Chief Legal Officer
Karin WierinckChief People Officer
Melissa Patterson Ph.D.Chief of Staff
Wen ShaChief of Staff
Dr. Christine Lemke D.V.M., M.B.A., Ph.D.Senior Vice President of Portfolio and Growth Strategy

Latest SEC Filings

DateTypeTitle
Jul 25, 2025424B5Filing
Jul 25, 20258-KCurrent Report
Jul 24, 2025424B5Filing
Jul 16, 2025SCHEDULE 13G/AFiling
Jul 8, 20258-KCurrent Report
Jun 12, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 14, 2025SCHEDULE 13G/AFiling
May 14, 2025SCHEDULE 13G/AFiling